Data Insights

Mirdametinib by SpringWorks Therapeutics for Non-Small Cell Lung Cancer: Likelihood of Approval

Mirdametinib is under clinical development by SpringWorks Therapeutics and currently in Phase II for Non-Small Cell Lung Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Mirdametinib in Non-Small Cell Lung Cancer

Data Insights

Mirdametinib by SpringWorks Therapeutics for Neurofibromatoses Type I (Von Recklinghausen's Disease): Likelihood of Approval

Mirdametinib is under clinical development by SpringWorks Therapeutics and currently in Pre-Registration for Neurofibromatoses Type I (Von Recklinghausen's Disease). According...

Likelihood of Approval and Phase Transition Success Rate Model - Mirdametinib in Neurofibromatoses Type I (Von Recklinghausen's Disease)

Data Insights

Mirdametinib by SpringWorks Therapeutics for Thyroid Cancer: Likelihood of Approval

Mirdametinib is under clinical development by SpringWorks Therapeutics and currently in Phase II for Thyroid Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Mirdametinib in Thyroid Cancer

Data Insights

Mirdametinib by SpringWorks Therapeutics for Endometrial Cancer: Likelihood of Approval

Mirdametinib is under clinical development by SpringWorks Therapeutics and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Mirdametinib in Endometrial Cancer

Data Insights

Mirdametinib by SpringWorks Therapeutics for Pancreatic Cancer: Likelihood of Approval

Mirdametinib is under clinical development by SpringWorks Therapeutics and currently in Phase II for Pancreatic Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Mirdametinib in Pancreatic Cancer

Data Insights

Mirdametinib by SpringWorks Therapeutics for Ovarian Cancer: Likelihood of Approval

Mirdametinib is under clinical development by SpringWorks Therapeutics and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Mirdametinib in Ovarian Cancer

Data Insights

Mirdametinib by SpringWorks Therapeutics for Solid Tumor: Likelihood of Approval

Mirdametinib is under clinical development by SpringWorks Therapeutics and currently in Phase II for Solid Tumor. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Mirdametinib in Solid Tumor

Data Insights

Risk adjusted net present value: What is the current valuation of SpringWorks Therapeutics's Mirdametinib?

Mirdametinib is a small molecule commercialized by SpringWorks Therapeutics, with a leading Pre-Registration program in Neurofibromatoses Type I (Von Recklinghausen's...

Net Present Value Model: SpringWorks Therapeutics Inc's Mirdametinib

Data Insights

Risk adjusted net present value: What is the current valuation of SpringWorks Therapeutics's Mirdametinib?

Mirdametinib is a small molecule commercialized by SpringWorks Therapeutics, with a leading Phase II program in Neurofibromatoses Type I (Von...

Net Present Value Model: SpringWorks Therapeutics Inc's Mirdametinib

Data Insights

Mirdametinib by SpringWorks Therapeutics for Low-Grade Glioma: Likelihood of Approval

Mirdametinib is under clinical development by SpringWorks Therapeutics and currently in Phase II for Low-Grade Glioma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Mirdametinib in Low-Grade Glioma